However, SHP-2 is expressed in macrophages and SHP-2 inhibitors can negatively regulate suppressive M2-type tumor-associated macrophages (Chen et al., 2020) which could positively influence the outcomes for cancer treatment. Here, PTPN11 is linked to neoplasm.